Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.
Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Brian Yang
As China moves to implement a raft of planned policy and regulatory changes, including opening up more to new drugs from multinationals, companies including Takeda appear to be ringing in personnel changes and increasingly hiring local executives to senior positions.
China is planning to enact changes that will view the intentional forging of clinical trial and other data submitted to gain drug approvals as a criminal offence, punishable by prison terms of up to three years.
A new dual receipting system, a potential registry for sales reps, and rules over false advertisements and promotion are just some of the many and growing challenges pressuring pharna corporate compliance officers in China, experts attending a recent conference said.
China is aggressively driving up life sciences innovations, leading the charge in technologies including gene editing and genome testing, prompting executives to take a fresh approach.
China’s big three, Baidu, Alibaba and Tencent, deepen involvement in healthcare, hiring talent and eyeing digital health platforms.
Delinking drug approvals from price agreements, and providing timely and adequate reimbursement coverage, are just some of the policy changes top big pharma executives would like to see if China is to create an operating environment conducive to innovation.